News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

BioWa And Aphton Corporation (APHT) Announce Licensing Of BioWa's POTELLIGENT(TM) Technology


2/14/2006 1:32:05 PM

PRINCETON, N.J. & PHILADELPHIA, Pa.--(BUSINESS WIRE)--Feb. 14, 2006--BioWa, Inc. and Aphton Corporation (Pink Sheets:APHT) today announced that BioWa has granted a non-exclusive license to Apthon's wholly-owned subsidiary, Igeneon, to use BioWa's POTELLIGENT(TM) technology for the development of IGN312, a humanized monoclonal Lewis Y-specific antibody. Aphton, through Igeneon, develops IGN312 as a next-generation antibody based on IGN311, which is currently in a Phase I/II clinical trial in patients with Lewis Y-positive cancers.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES